The promise of neuroprotective agents in Parkinson’s disease

Stacey E. Seidl1 and Judith A. Potashkin2*

1 Department of Biological Sciences, DePaul University, Chicago, IL, USA
2 Department of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

INTRODUCTION

Parkinson’s disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dysfunction, and inflammation are prime candidates for neuroprotection. This review identifies Rasagiline, Minocycline, and creatine, as the most promising neuroprotective agents for PD, and they are all currently in phase III trials. Other agents possessing protective characteristics in delaying PD include stimulants, vitamins, supplements, and other drugs. Additionally, combination therapies also show benefits in slowing PD progression. The identification of neuroprotective agents for PD provides us with therapeutic opportunities for modifying the course of disease progression and, perhaps, reducing the risk of onset when preclinical biomarkers become available.

Keywords: neuroprotection, neurodegeneration, Parkinson’s disease

CAFFEINE AND NICOTINE ARE PROMISING NEUROPROTECTIVE STIMULANTS FOR PARKINSON’S DISEASE

Most epidemiological studies support a protective benefit of drinking caffeinated beverages (Ross et al., 2000; Ascherio et al., 2001; Saaksjarvi et al., 2008), although one study showed no benefit (Xu et al., 2006). Animal studies in general also indicate that caffeine is neuroprotective. Chronic caffeine administration in mice provided protection against dopaminergic neuron toxicity from exposure to a combination of paraquat and maneb (van den Pol, 1986; Kachroo et al., 2010). In addition, acute and chronic treatment of mice with caffeine reduced the effect of acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) (Chen et al., 2001) and 6-hydroxydopamine (6-OHDA) treatment on striatal DA loss (Joghataie et al., 2004). Motor dysfunctions were attenuated and DA levels increased after caffeine treatment in MPTP and 6-OHDA-treated animals (Joghataie et al., 2004; Aguiar et al., 2006). In addition, caffeine treatment partially restored noradrenaline, DA, 3,4 dihydroxypheylacetic acid, homovanillic acid, and their metabolites in 6-OHDA-lesioned rats (Aguiar et al., 2006). Although serotonin levels decreased, levels of its metabolite, 5-hydroxyindoleacetic acid, were unchanged. In treatment, the time frame of caffeine’s beneficial effects is extended by its metabolites theophylline and paraxanthine, which also exert protective effects (Xu et al., 2010). An additional benefit of caffeine is that tolerance does not develop with long-term exposure (Xu et al., 2002).

The effect of estrogen on caffeine’s neuroprotective capabilities is significant. Results from epidemiological studies showed improvement in male Parkinson’s patients only (Ascherio et al., 2001; Costa et al., 2010). Interestingly, in post-menopausal women, caffeine consumption is also linked to a reduced risk of PD, but only among those who were not taking hormone-replacement therapy (Ascherio et al., 2003). In a follow up case-controlled study the relationships between gender, caffeine intake, estrogen, and the risk of PD were examined by investigating single nucleotide polymorphisms (SNPs) in the caffeine metabolizing genes [the cytochrome P450 (CYP) gene CYP1A2 and N-acetyltransferase 2 (NAT2)] and estrogen receptors (ERα and ERβ). A significant increased risk of PD was observed in women who had the CYP1A2 polymorphism, whereas NAT2, ERα, and ERβ had marginal effects on PD risk (Palacios et al., 2010). In another study, estrogen and caffeine were administered to both male and female...
MPTP-treated mice, which prevented neuroprotection in all of the animals (Xu et al., 2006). Thus, the beneficial effects of caffeine may be limited to men and post-menopausal women who are not receiving hormone-replacement therapy.

Complimentary genetic and pharmacological data from rodent studies indicate that one mechanism by which caffeine reduces dopaminergic toxicity is through antagonism of adenosine A2A receptors (see review Prediger, 2010). In contrast, the indirect pathway of the basal ganglia contributes to the progression of PD via glutamatergic neuron overstimulation through adenosine A2A receptors (Bove et al., 2005b). Caffeine also activates PI3K/Akt signaling and thus reduces apoptosis (Nakaso et al., 2008).

Nicotine is comparable to caffeine with regards to lowering the risk of developing PD (Simon et al., 2009). In a Chinese epidemiological study, there was a significant reduced rate of PD in individuals who drank coffee and smoked cigarettes, which was dose-dependent (Tan et al., 2003). Toxicant responsive enzymes, including CYP1A1, CYP2E1, and glutathione S-transferase (GST) enzymes GST-ya, GST-yc, GSTA4-4, and vesicular monoamine transporter-2 play critical roles in modulating the protective effects of nicotine and caffeine in MPTP-treated animals (Singh et al., 2008). Interestingly, decaffeinated coffee and nicotine-free tobacco were neuroprotective in a Drosophila model of PD, but, the neuroprotection depended on the cytoprotective transcription factor nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) and cafestol (an activator) (Trinh et al., 2010). This suggests that coffee and tobacco containing Nrf2-activating compounds account for the decreased risk of PD.

Nicotine without caffeine, has also shown beneficial effects in reducing the risk of PD in epidemiological studies and animal studies (reviewed in Quick, 2004). Animals receiving nicotine at low doses (0.1 mg/kg s.c) in vitro showed reduce DA depletion resulting from MPTP and 6-OHDA treatments (Ferger et al., 1998; Costa et al., 2001). A large dosage of nicotine (0.4 mg/kg s.c), however, enhanced dopamine loss in vivo (Ferger et al., 1998). Additionally, nicotine attenuated motor deficits and nigrostriatal neurodegeneration produced by chronic administration of rotenone in mice. In 6-OHDA-lesioned rats, subchronic nicotine (0.4 mg/kg) and apomorphine treatment reduced parkinsonian contralateral rotations (Meshul et al., 2002). Chronic nicotine treatment in MPTP-treated primates restored and maintained dopaminergic function and prevented cell loss in the SNpc (Quick et al., 2006). In addition, simple exposure to tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice (Carr and Rowell, 1990). Additionally, in humans, acute nicotine treatment can improve impaired controlled semantic processing in PD patients (Holmes et al., 2011). To date, nicotine is still in Phase II trials focusing on optimizing dosage and increasing sample size.

Nicotine is an alkaloid that is the predominant ingredient found in cigarettes. It has a high rate of absorption and diffuses quickly through the bloodstream and across the blood-brain barrier (BBB). Nicotine reduces the oxidative stress that is associated with the progression of PD by scavenging free radicals produced by monoamine oxidase-B (MAO-B), which metabolizes DA (Fowler et al., 1996; Iida et al., 1999). In addition, nicotine is capable of augmenting neurotrophic factors and cholinergic receptor expression (Ferreira and Winterer, 2009). Nicotine pretreatment attenuated the loss of dopaminergic cells in MPTP-induced mesencephalic neurons (Quick and Jeyarasasingam, 2000). Neuroprotection was blocked by a nicotine receptor antagonist suggesting the effect was mediated by nicotinic acetylcholine receptors (nAChR; Quik and Jeyarasasingam, 2000). These results suggest that the neuroprotective mechanism of nicotine may be directly or indirectly connected to the nAChR up-regulation in cerebral cortical blood flow (Linville et al., 1993). Moreover, it indicates that nAChR agonists could be beneficial in slowing the progression of PD (Maggio et al., 1997). Recently it has been suggested that stimulating nAChRs or PI3K/Akt/PKB signaling could suppress dopaminergic cell death induced by rotenone (Takeuchi et al., 2009). In similar studies, nicotine induced fibroblast growth factor (FGF-2) and the brain-derived neurotrophic factor (BDNF) in the striatum (Maggio et al., 1997). Neuroprotection of DA neurons by nicotine is primarily gated by cytoplasmic Ca²⁺ through a mechanism involving α-bungarotoxin-sensitive (α7) nAChRs and secondarily through T-type voltage-gated calcium channels (Toulorge et al., 2011).

URATE AND URIC ACID HAVE MODERATE NEUROPROTECTIVE PROPERTIES

Uric acid (UA) is a natural antioxidant that can reduce oxidative stress by acting as a scavenger of free radicals and an iron chealator (Ames et al., 1981; Davies et al., 1986; Yu et al., 1998; Hink et al., 2002). Urate suppresses oxyradical accumulation (Yu et al., 1998), inhibits cytotoxic activity of lactoperoxidase (Everse and Coates, 2004), and protects against DA-induced apoptosis (Jones et al., 2000). UA has been found to suppress oxidative stress and prevent dopaminergic cell death in animals (Duan et al., 2002). In addition, slower rates of clinical progression were observed in untreated early stage PD patients who have higher plasma, serum, and cerebrospinal fluid (CSF) concentrations of UA (Schwarzschild et al., 2008; Ascherio et al., 2009). In contrast, lower levels of urate were present in CSF (Tohgi et al., 1993) and post-mortem in the SNpc of patients with PD (Church and Ward, 1994). In a population-based cohort study of 4,695 participants aged 55 years and older, higher serum levels of UA were associated with a significantly decreased risk of PD (de Lau et al., 2005). Urate therapy reduced the risk of PD in a dose-dependent manner (de Lau et al., 2005; Schwarzschild et al., 2008). Additionally in a prospective study of subjects with early stage PD there was a 49% reduction in the progression of the disease with high urate intake (Schwarzschild et al., 2008).

Like caffeine, urate (Alonso et al., 2007) and UA (Alonso et al., 2007; Schwarzschild et al., 2008; Andreadou et al., 2009) show a gender-specific bias with a greater benefit observed in male PD patients. Epidemiological studies however contradict these results and show no gender specificity (de Lau et al., 2005; Annanmaki et al., 2007; Chen et al., 2009).

Life style choices play an important role in PD progression. Exercising, for example, decreases PD, possibly by increasing serum UA levels and decreasing excretion of UA (Schlesinger and Schlesinger, 2008). Additionally, individuals who eat diets that increase plasma urate levels have a reduced risk of PD. Dietary changes expected to increase plasma urate levels include dairy protein (but not milk) (Choi et al., 2005) and vitamin C contribute to reducing the risk of PD in men (Gao et al., 2008). These studies also
suggest that a PD patient’s diet should include adequate sources of purines, such as meat and seafood, which results in higher concentrations of UA (Annamaki et al., 2007). Diets that result in lower UA levels could accelerate disease progression (Annamaki et al., 2007). One must keep in mind however that a high concentration of UA in the blood serum increases the risk of gout and high alcohol and fructose consumption compounds this risk (Choi et al., 2004). Therefore, even if PD patients choose to modify their diet for potential neuroprotective effects, the physician must carefully monitor them for other at risk chronic diseases (Gao et al., 2008).

**VITAMIN D, BETA-CAROTENE AND RIBOFLAVIN ARE CANDIDATES FOR NEUROPROTECTIVE AGENTS**

Vitamin E (α-tocopherol) is a lipid-soluble antioxidant that can inhibit iron accumulation, suppress microglial activation, scavenge oxygen radicals, and prohibits the peroxidation of membrane lipids (Tappel, 1962; Burton et al., 1983; Cheeseman et al., 1988; Chow, 1991; Lan and Jiang, 1997; Li et al., 2001). Vitamin E also induces interleukin-1α and tumor necrosis factor (TNF-α) and suppresses p38 MAPK and NFκB activation (Li et al., 2001). Vitamin E is regulated by α-tocopherol transfer protein (TTP) in the liver and brain (Kaempf-Rotzoll et al., 2003). Studies have demonstrated that lack of TTP causes a systemic deficiency of vitamin E in humans and mice (Traber and Sies, 1996; Yokota et al., 2001), which can lead to enhanced oxidative stress in the brain (Yokota et al., 2001). However, vitamin E is also believed to reduce oxidative stress caused by iron accumulation in the brain (Lan and Jiang, 1997). Vitamin E deficiency increases MPTP toxicity in mice (Odunze et al., 1990). Vitamin E supplementation, however, had a protective effect on DA neurons in the SNpc (Roghani and Behzadi, 2001) and reduced DA loss (Lan and Jiang, 1997). Pretreatment with vitamin E was shown to reduce lipid peroxidation levels (Lan and Jiang, 1997), but depletion of striatal DA was not attenuated by pretreatment (Gong et al., 1991; Chi et al., 1992). Other studies have shown that vitamin E has no protective effects against DA-induced toxicity in PC12 cells (Offen et al., 1996) and only partial protection in MPTP-treated rodents (Perry et al., 1987). In addition, a genetic vitamin E deficiency did not affect MPTP susceptibility in mice (Ren et al., 2006). So either the protective effects of vitamin E is dependent on the mechanism by which PD is induced or high acute dose of vitamin E have different neuroprotective effects than chronic low doses (Fariss and Zhang, 2007; Ricciarelli et al., 2007).

There are no differences in the amount of vitamin E in the cerebellum (Dexter et al., 1992) or CSF (Molina et al., 1997) between PD patients and healthy individuals. Clinical trials also show no neuroprotective benefit of taking vitamin E (Fernandez-Calle et al., 1992; LeWitt, 1994; Morens et al., 1981). A meta-analysis however showed a protective effect of both moderate intake (0.67–0.98) and high intake (0.78, 0.57–1.06) of vitamin E (Etminan et al., 2005). Thus, choosing foods that are vitamin E-rich may be neuroprotective (Perlmutter, 1988). Vitamin A’s precursor beta-carotene, may offer neuroprotective effects by preventing lipid peroxidation (Glover, 1960; Kartha and Krishnamurthy, 1977). A recent study showed that pretreatment with beta-carotene partially protected against MPTP-induced neurotoxicity in mice (Perry et al., 1985; Yong et al., 1986), although the same was not true of primates (Perry et al., 1987).

Riboflavin, vitamin B-2, is a water-soluble vitamin present predominantly in dairy products (Powers, 2003). Its biologically active forms are flavin adenine dinucleotide and flavin mononucleotide, which are electron carriers that participate in a wide range of redox reactions (Huennekens, 1956; Merrill et al., 1981). Riboflavin plays an active role in energy production and affects iron accumulation (Sririvech et al., 1977; Powers et al., 1983; Powers, 1987). The mechanism of action of riboflavin in the brain remains unknown.
but may involve glutathione depletion, cumulative mitochondrial DNA mutations, disturbed mitochondrial protein complexes, and abnormal iron metabolism (Di Monte, 1991; Jenner et al., 1992; Logroscino et al., 1997). Riboflavin may also effect glutathione production (Perlmutter, 1988). The amount of riboflavin is lower in PD patients compared to healthy and disease controls, suggesting that taking riboflavin supplements may be beneficial (Coimbra and Junqueira, 2003). Intake of riboflavin, compared to other B-vitamins was shown to reduce the risk of PD (Murakami et al., 2010). In fact, the risk of PD was reduced 51% by users obtaining a high consumption (Perlmutter, 1988) and daily doses of riboflavin for 6 months showed improved motor capacity of PD patients in 3 months (Coimbra and Junqueira, 2003). These promising results indicate that additional longitudinal studies are needed to determine the long-term effects of chronic administration of riboflavin supplements.

**AMONG THE SUPPLEMENTS CREATINE SHOWS THE MOST PROMISE AS A NEUROPROTECTIVE AGENT**

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a promising agent for neuroprotection in PD and other neurodegenerative diseases because of its role in the mitochondrial electron transport chain (METC) and as an antioxidant (Beal and Shults, 2003). CoQ10 serves as an electron acceptor in complex I and II of the METC. CoQ10 is protective by inhibiting SIN-1-induced apoptosis (Sharma et al., 2004), suppressing intra-mitochondrial and intra-nuclear biosynthesis of 8-OH-2dG, inhibiting translocation of caspase-3, attenuating α-synuclein expression, and blocking intra-mitochondrial accumulation of metal ions (Ebadi et al., 2004).

Animal studies have shown that rotenone-induced parkinsonism reduced CoQ10 concentrations in plasma and the striatum with a corresponding decrease in striatal levels of DA, mitochondrial complex I activity and ATP levels, as well as significant increase in B-cell lymphoma 2 (Bcl-2) expression (Abdin and Hamouda, 2008). Administration of CoQ10 protected the nigrostriatal dopaminergic neurons in MPTP-treated mice (Shults et al., 1997, 1999). In addition, a diet containing CoQ10 (1,600 mg/kg/day, 2 months) or CoQ10 supplementation diminished neuronal tissue damage (Cleren et al., 2008). CoQ10 was also effective in preventing DA depletion, loss of tyrosine hydroxylase neurons and formation of α-synuclein inclusions in the SNpc in mice (Cleren et al., 2008).

Reduced levels of CoQ10 are present in PD patients' plasma and platelets (Matsubara et al., 1991; Gotz et al., 2000) and in cortex (Hargreaves et al., 2008), which correlated with reduced activity of complex I and II/III (Shults et al., 1997, 1999). In addition, the percent of CoQ10 in its oxidized form is elevated in PD patients (Sohmiya et al., 2004). Chronic administration of CoQ10 in PD patients delays the progression of PD (Shults et al., 2002; Shults, 2003) with no adverse effects (Galpern and Cudkowicz, 2008). Additionally, CoQ10 supplements showed promising results in a small group of nevo PD patients during phase II clinical trials although no follow up study has been published (Shults et al., 2002). More recently, another human trial found inconclusive results from CoQ10 supplements in PD patients (Investigators, 2007). CoQ10 (2,400 mg/day) and vitamin E (1,200 IU/day) together initially was thought to be beneficial for PD patients (Shults et al., 2004), however, in Phase III trials it was deemed futile (NINDS).

Creatine is a guanidino compound found primarily in meat products and is produced endogenously by the liver, kidney, and pancreas (Tarnopolsky and Beal, 2001; Adhihetty and Beal, 2008). Creatine possesses antioxidant properties and can regulate intracellular calcium, suppress extracellular glutamate levels, and inhibit the opening of the mitochondrial permeability transition pore (MPT; [Figure 1]) (Xu et al., 1996; Lawler et al., 2002; Dedegolu et al., 2003).

A combination of CoQ10 and creatine shows an additive neuroprotective effect in chronic MPTP-treated mice (Yang et al., 2009). Additionally, creatine has shown promising neuroprotective effects in combination with CoQ10 in PD patients (Yang et al., 2009). Alone, creatine protects against MPTP-induced DA depletion in the SNpc (Matthews et al., 1999). Interestingly, in a stage II clinical trial creatine showed a delay in the progression of PD by 50% compared to controls that received a placebo (Investigators, 2006). In a follow up study 18 months later, creatine continued to show efficacy as a neuroprotective agent (Investigators, 2008) and it is currently in Phase III trials (NET-PDLS).

---

1. [http://www.ninds.nih.gov/disorders/clinical_trials/CotQ10-Trial-Update.htm](http://www.ninds.nih.gov/disorders/clinical_trials/CotQ10-Trial-Update.htm)

2. [http://clinicaltrials.gov/ct2/show/NCT00449865](http://clinicaltrials.gov/ct2/show/NCT00449865)
Omega-3 polyunsaturated fatty acids appear to be neuroprotective for several diseases (Bousquet et al., 2011) including a small study with PD patients (da Silva et al., 2008). Animal studies have shown that the omega-3 fatty acid docosahexaenoic acid (DHA) can replace the omega-6 fatty acids already present in the brains of mice that had been given supplements after MPTP treatment (Bousquet et al., 2008). DHA is an essential factor in growth and development in the brain (Horrocks and Yeo, 1999) and has anti-inflammatory capabilities due to its ability to inhibit cyclo-oxygenase-2 (COX-2) (Massaro et al., 2006). DHA (5–50 μg/ml) protected neurons against cytotoxicity, inhibited both nitrogen oxide (NO) production and Ca²⁺ influx, and increased the activities of antioxidant enzymes of glutathione peroxidase and glutathione reductase (Wang et al., 2003) in cell cultures. DHA does not alter the levels of glutathione (GSH) (Wang et al., 2003). Animal studies showed that DHA decreased apoptosis of dopaminergic cells after MPTP treatment (Ozsoy et al., 2011). Short-term administration of DHA (100 mg/kg) reduced 40% of the levodopa-induced dyskinesias in Parkinsonian primates (Samadi et al., 2006). DHA also preserved DA levels, tyrosine hydroxylase (TH)-positive neurons and nuclear receptor related-1 protein expression from MPTP-induced neurotoxicity in mice (Bousquet et al., 2008). Chronic administration of uridine and DHA increased the levels of neural phosphatides and proteins in synaptic membranes (Wurtman et al., 2006) and dendritic spines in rodents (Sakamoto et al., 2007). DHA and uridine administration also reduced parkinsonian related behaviors and elevated DA levels in 6-OHDA rats (Cansev et al., 2008). Human studies on the effects of DHA are now needed before recommendations may be made to PD patients.

DHA's proposed mechanisms of neuroprotection are linked to its anti-oxidative activity in vivo (Hashimoto et al., 2002; Yavin et al., 2002; Calon et al., 2004; Wu et al., 2004; Bazan, 2005), its ability to increase glutathione reductase activity (Hashimoto et al., 2002) and decrease the accumulation of oxidized proteins (Calon et al., 2004; Wu et al., 2004) and levels of lipid peroxide and reactive oxygen species (ROS) (Hashimoto et al., 2002, 2005). DHA also triggered inactivation of cell-signaling pathways leading to caspase activation (Calon et al., 2004, 2005) and hyperphosphorylation of tau (Green et al., 2007). In addition, DHA regulates the PI3K/Akt cascade (Akbar and Kim, 2002; Akbar et al., 2005; Kim, 2007). DHA has no association with beta-secretase or gamma-secretase complex, but it can down-regulate presenilin-1 in vitro and in vivo (Lim et al., 2005; Green et al., 2007). Other potential mechanisms of action of DHA include regulation of inflammation, gene transcription, and cell membrane properties (de Urquiza et al., 2000; Salem et al., 2001; Jump, 2002).

Melatonin has been associated with nigrostriatal protection, reduced auto-oxidation of l-3,4-dihydroxyphenylalanine, and has antioxidant properties (Fertil et al., 1993; Miller et al., 1996; Reiter et al., 1997; Khalbly et al., 2000; Rocchitta et al., 2006). Decreased levels of melatonin are present in PD patients compared to controls (Sandyk, 1990). Melatonin’s free radical scavenging properties and its ability to easily pass the BBB suggest that it may be neuroprotective (Antolin et al., 2002; see review Mayo et al., 2005).

Animal studies have shown that melatonin can prevent cell death and damage induced by MPTP (Acuna-Gastroviejo et al., 1997), 6-OHDA (Kim et al., 1998), and iron (Maharaj et al., 2006a) in neurons and astrocytes (Martin et al., 2002). Melatonin blocked apoptosis and necrosis in 6-OHDA-treated undifferentiated and nerve growth factor (NGF)-differentiated PC12 cells (Mayo et al., 1998, 1999). Contrary to these results, striatal DA depletion and DA neuron loss increased after melatonin treatment of rotenone-induced Parkinsonism (Tapias et al., 2010). Melatonin given to PD patients improved the duration of sleep and reduced sleep disturbances (Dowling et al., 2005). There are no clinical studies to date that have investigated whether melatonin is neuroprotective for PD patients.

The antioxidant GSH, which is involved in iron metabolism and plays an ancillary role in thiol–redox control, is depleted in the SNpc of PD patients (Perry et al., 1982; Riederer et al., 1989; Pearce et al., 1997). When GSH was depleted in vitro and in vivo, there was oxidative damage of complex I proteins (Chinta and Andersen, 2006; Chinta et al., 2007; Kumar et al., 2011), defects in basal ganglia formed (Sian et al., 1994), and the ubiquitin–proteasome system functioned poorly (Martin and Teismann, 2009), but the electron transport chain complex was unaffected (Heales et al., 2011). Collectively these studies suggest that GSH may facilitate cascading events leading to oxidative stress (Bharath et al., 2002; Garrido et al., 2011).

Animal studies have also shown that excessive or reduced GSH levels can initiate degeneration of DA neurons (Garrido et al., 2011). However, chronically decreased GSH concentrations in the brain did not directly correlate to a reduction in the viability of DA neurons in the SNpc, nor decrease the number of striatal DA terminals, but does make neurons more susceptible to neurotoxins (Schulz et al., 2000). Treatment with MPTP in GSH peroxidase-deficient mice resulted in depletion of DA (Klivenyi et al., 2000). In nigral TH immune responsive cells similar results were seen with a greater reduction of DA neurons when lower levels of GSH were present prior to toxin administration (Pileblad et al., 1989; Seaton et al., 1996; Wullner et al., 1996). These studies suggest that the concentration of GSH is key to its neuroprotective capabilities. It has been hypothesized that enhancement of GSH synthesis or inhibition of its degradation may result in a decrease in disease progression (Schulz et al., 2000).

Phytic acid (IP6) is a naturally occurring iron chelator in food that acts by altering cell-signaling pathways and the activity or expression of antioxidant enzymes (Shamsuddin et al., 1997; Xu et al., 2011). IP6 is capable of inhibiting MPTP, 6-OHDA, and iron toxicity in cell culture (Xu et al., 2008, 2011). IP6 increases cell survival in MPTP-treated cells and repressed caspase-3 activity and DNA fragmentation (Xu et al., 2008). IP6 also suppressed hydroxyl radical formation after 1-methyl-4-phenylpyridinium (MPP+) treatment in rats (Obata, 2003). Further animal and human studies are needed to test IP6’s antioxidant’s properties.

SEVERAL COMMONLY PRESCRIBED DRUGS ARE EMERGING AS THERAPEUTIC AGENTS FOR PD

Common household drugs such as aspirin and Ibuprofen protect against neuro-inflammation, which can lead to neurodegeneration in the brain (Hirsch and Hunot, 2009). The use of non-steroidal anti-inflammatory drugs (NSAIDS) has been shown to lower the risk of PD in epidemiological studies (Chen et al., 2003; Tön et al., 2003).
Acetaminophen (Chen et al., 2005; Ton et al., 2006; Driver et al., 2009) and protect against neuronal death, ROS/peroxidation, and dopaminergic neurotoxicity by inhibiting cyclo-oxygenase enzymes in animals (Blodeau et al., 1995; Kaufmann et al., 1997; Aubin et al., 1998; Saini et al., 1998; Casper et al., 2000; Sairam et al., 2003). Pretreatment with NSAIDS is neuroprotective in MPTP and 6-OHDA-treated animals and in vitro (Esposito et al., 2007). In humans there was a reduction in PD risk observed in individuals who use Ibuprofen, but no reduction was found in individuals who use NSAIDS or Acetaminophen (Chen et al., 2005; Ton et al., 2006; Driver et al., 2011; Gao et al., 2011). A case-controlled study also concluded that NSAID's and aspirin show no association with altering the risk of PD (Becker et al., 2011). In some studies there was a reported increased risk of PD observed in individual who use aspirin (Bower et al., 2006; Hernan et al., 2006). In contrast, other studies showed that aspirin was protective and functioned by ROS scavenging in vivo (Di Matteo et al., 2006; Maharaj et al., 2006b). Ibuprofen protects DA neurons against glutamate toxicity and decreases MPTP toxicity in vitro (Casper et al., 2000; Morioka et al., 2004; Carrasco et al., 2005). A meta-analysis determined that regular use of Ibuprofen also reduced the risk of developing PD in humans by 40% (Samii et al., 2009; Gao et al., 2011). The results from these studies together suggest that Ibuprofen and aspirin may be neuroprotective.

The dihydropyridine L-type calcium channel blocker Isradipine has been reported to reduce hypoxia-induced activation of Ca^{2+}-dependent xanthine oxidases, monoamine oxidases, cytosolic phospholipase A2, and cyclo-oxygenases (COX-2) along with a decrease in free radical generation and cytochrome-c release (Barhwal et al., 2009). Increased expression of calpain, caspase-3, (Barhwal et al., 2009), and glutamate-induced neurotoxicity (Pizzi et al., 1991) was also inhibited by Isradipine.

The use of L-type Ca^{2+} channel antagonists protects SNpc DA neurons in MPTP-treated animals (Kupsch et al., 1995, 1996; Chan et al., 2007), but the same was not true of 6-OHDA-treated animals (Sautter et al., 1997). This discrepancy may be the result of the different mechanisms by which the two toxins act on mitochondria (Bove et al., 2005a). Currently very few studies specifically address Isradipine's neuroprotective capabilities, however a dose-dependent effect was observed in 6-OHDA-treated animals (Ilijic et al., 2011). In a pilot study in which PD patients were treated with Isradipine no negative side effects were noted thus paving the way for further clinical testing (Simuni et al., 2010).

Because a mutation in the DJ-1 protein causes early onset of autosomal PD (Bonifati et al., 2003; Ibanez et al., 2003) and lower levels of DJ-1 are associated with PD, it is thought that drugs that up-regulate DJ-1 may slow disease progression by moderating oxidative stress and protein aggregation (Zhou et al., 2011). DJ-1 acts through multiple pathways, and works in parallel with PINK1/parkin (Zhou et al., 2011). Phenylbutyrate, a chaperone molecule and histone deacetylase inhibitor, increased DJ-1 expression in DA cell cultures, rescued cells from oxidative stress, and reduced α-synuclein aggregation (Zhou et al., 2011). In MPTP-treated animals, phenylbutyrate protected DA neurons in the SNpc and increase DJ-1 expression (Gardian et al., 2004; Zhou et al., 2011). Long-term administration of phenylbutyrate reduced deterioration in motor and cognitive functions in mice (Zhou et al., 2011). Similar results were seen with 4-phenylbutyrate in rotenone-treated mice (Inden et al., 2007).

Type 2 diabetes has been correlated with an increase risk of PD and a high prevalence of insulin resistance has been found in PD patients, suggesting that the two chronic diseases may share similar dysregulated pathways that play a role in cell death and dysfunction (Arvanitakis et al., 2004; Jeerkathil et al., 2007). Possible shared pathways may be related to insulin regulation, suggesting that diabetes drugs may possess neuroprotective effects (Holst et al., 2011). Glucagon-like peptide-1 (GLP-1) is commonly used to treat type 2 diabetes. GLP-1 also acts as a growth factor in the brain, and can induce neurite outgrowth and protect against oxidative injury in cultured neuronal cells (Perry et al., 2007). The anti-apoptotic actions of GLP-1 is thought to be related to the activation of the transcription factor CAMP response element-binding protein by phosphorylation (Perry et al., 2002; Li et al., 2009). Previous studies have also claimed that PDA, PI3K, and MAPK may be involved in the mechanism of action of GLP-1, in addition to MAPK-independent signaling and growth factor-dependent Ser/Thr kinase AktPKB (Lazaroff et al., 1995; During et al., 2003; Perry and Greig, 2005).

Exendin-4 (Ex-4), an analog of GLP-1, protected DA neurons from degeneration, preserved DA levels, and improved motor function in rodents (Li et al., 2009) by inhibiting microglial activation and matrix metalloproteinase-3 expression (Kim et al., 2009). Ex-4 has also been shown to protect ventral mesencephalic dopaminergic cells in culture, reverse nigral lesions, and protect against 6-OHDA toxicity (Harkavyi et al., 2008; Li et al., 2009). Ex-4 receptors also show neuroprotection by mediating and increasing neurogenesis in the subventricular zone in rodents (Bertilsson et al., 2008). In addition to Ex-4, other analogs of GLP-1 offer promising neuroprotective effects (see review Harkavyi and Whitton, 2010). One of these, Liraglutide, has been shown to be neuroprotective in an Alzheimer’s disease model (McClean et al., 2010, 2011).

**RASAGILINE AND MINOCYCLINE ARE CURRENTLY IN CLINICAL TRIALS AS NEUROPROTECTIVE AGENTS FOR PD**

Rasagiline is a selective and potent propargylamine MAO-B inhibitor (Tatton et al., 2003), that reduces MPTP and 6-OHDA toxicity in PC12 and SH-SY5Y cells, (Maruyama et al., 2000) and is neuroprotective in vivo (Heikkila et al., 1985; Huang et al., 1999; Speiser et al., 1999; Sagi et al., 2001; Youdim et al., 2001a). Pretreatment with Rasagiline prevents nigrostriatal damage induced by MPTP in primates (Kupsch et al., 2001; Sagi et al., 2001). Chronic administration of Rasagiline increased DA neuron survival in lesioned SNpc and improved motor impairments (Bladini et al., 2004). Rasagiline also increased the expression of the neurotrophins BDNF, GDNF, and NGF (Murer et al., 2001). In humans, Rasagiline reduced the long-term progression and symptoms in PD (Hauser et al., 2009; Olanow et al., 2009). In a promising recent study, Rasagiline delayed the need for antiparkinsonian drugs and patients had lower scores on the PD rating scale in a Phase III study (Rascal et al., 2011).

Rasagiline suppresses mitochondrial apoptosis by inhibiting caspase-3 and nuclear poly [ADP-ribose] polymerase 1.
| Neuroprotective agents | Cell culture and animal studies | Human and epidemiological studies |
|------------------------|---------------------------------|----------------------------------|
| **Study**              | **Results**                     | **Study**                        | **Results** |
| **Caffeine**           | A (van den Pol, 1986; Kachroo et al., 2010) | Decreased dopaminergic neuron toxicity in MPTP | E (Ross et al., 2000; Ascherio et al., 2001)*, (Saaksjarvi et al., 2008; Costa et al., 2010)* | Caffeinated beverages decreased the risk of PD |
|                        | A (Chen et al., 2001; Joghataie et al., 2004; Aguiar et al., 2006) | Decreased DA loss and restored DA levels in MPTP and 6-OHDA | E (Xu et al., 2006) | Caffeinated beverages have no effect on PD risk |
|                        | A (Joghataie et al., 2004; Aguiar et al., 2006) | Decreased motor dysfunctions in 6-OHDA | H (Ascherio et al., 2003) | A decrease in PD risk among women consuming caffeine and not taking hormone-replacement therapy |
|                        | A (Xu et al., 2002, 2010) | Caffeine increased metabolites associated with prevention of DA loss | E (Tan et al., 2003) | Caffeine and nicotine combined reduced the rate of PD |
|                        | A (Xu et al., 2006) | Estrogen and caffeine prevented neuroprotection | H (Ascherio et al., 2009) | Nicotine lowered the risk of developing PD |
| **Caffeine + nicotine**| A (Trinh et al., 2010) | Decaffeinated coffee and nicotine-free tobacco were neuroprotective in Drosophila | E (Tan et al., 2003) | Caffeine and nicotine combined reduced the rate of PD |
| **Nicotine**           | A (Ferger et al., 1998; Costa et al., 2001) | Nicotine reduced DA depletion resulting from MPTP and 6-OHDA | E (Quick, 2004; Simon et al., 2009) | Nicotine lowered the risk of developing PD |
|                        | A (Mesulam et al., 2002) | Nicotine minimized parkinsonian contralateral rotations in 6-OHDA | Non-human primates maintained dopaminergic function and cell loss in the SNpc was prevented with nicotine administration | |
|                        | A (Quik et al., 2006) | Non-human primates maintained dopaminergic function and cell loss in the SNpc was prevented with nicotine administration | Tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice | |
|                        | A (Carr and Rowell, 1990)* | Tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice | |
| **Urate and UA**       | A/C (Jones et al., 2000; Duan et al., 2002) | UA protects against DA-induced apoptosis | E (de Lau et al., 2005; Alonso et al., 2007; Annannaki et al., 2007; Chen et al., 2009)*, (Schwarzschild et al., 2008)*, (Andreadou et al., 2009)* | Decreased risk of PD with UA and urate |
|                        | | | H (Ascherio et al., 2009) | |
|                        | | | H (de Lau et al., 2005; Schwarzschild et al., 2008) | Slower rates of clinical progression of PD were seen with UA intake |
|                        | | | E (Zhang et al., 2002; Etrman et al., 2005)* | Serum UA correlates with a decreased risk of PD |
|                        | | | H (Fernandez-Calle et al., 1992; LeWitt, 1994; Morens et al., 1996) | Protection from PD with moderate vitamin E intake |
|                        | | | Clinical trials also show no neuroprotective benefits of taking vitamin E | |

(Continued)
| Neuroprotective agents | Cell culture and animal studies | Human and epidemiological studies |
|------------------------|--------------------------------|-----------------------------------|
| Vitamin E + vitamin C  | Both vitamins combined decreased PD progression in early stage patients. |                                    |
| Vitamin C              | Few beneficial effects are seen with vitamin C and even an increased risk of PD. | Vitamin C intake reduced the risk of PD by 40%. |
| Vitamin D              | Disruption of Vitamin D's Ca²⁺ homeostasis properties accelerated SNpc dopaminergic neuron loss. | An increased risk of PD is associated with high consumption of vitamin D. |
|                        | GDNF stimulation by Vitamin D can alleviated PD symptoms in primates and PD patients. |                                    |
|                        | Vitamin D produced beneficial effects against PD characteristics. |                                    |
|                        | Vitamin D increased neuromuscular function in parkinsonian rodents. |                                    |
| Beta-carotene          | Beta-carotene protected against MPTP neurotoxicity in mice, but not primates. | A decrease in the risk of PD was seen with high B-carotene intake. |
| Riboflavin             | Reduced risk of PD, with high riboflavin intake by 51%. | Riboflavin supplementation improved motor capacity of PD patients. |
| CoQ10                  | CoQ10 protected nigrostriatal dopaminergic neurons in MPTP. | Chronic administration of CoQ10 delayed progression of PD in patients with no adverse affects in Phase II. |
|                        | CoQ10 supplementation diminished neural tissue damage and prevented DA depletion in SNpc. | Inconclusive results of CoQ10 supplement showing neuroprotection in PD patients. |
| CoQ10 + vitamin E      | Combination showed beneficial for PD patients, however, Phase III trials deemed it futile (NINDS, see text footnote 1). | Combination showed efficacy as a neuroprotective agent in PD and is currently in Phase III trials (NET-PDLS, see text footnote 2). |
| Creatine               | Creatine protected against MPTP-induced DA depletion in the SNpc. | Creatine delayed the progression of PD by 50%. |
| CoQ10 + creatine       | Combination showed a neuroprotective effect in chronic MPTP and humans. |                                    |
Table 1 | Continued

| Neuroprotective agents | Cell culture and animal studies | Human and epidemiological studies |
|------------------------|---------------------------------|----------------------------------|
|                        | Study                           | Results                          | Study | Results |
| **DHA**                | A (Bousquet et al., 2008)       | DHA supplements replaced omega-6 fatty acids after MPTP |            |         |
|                        | C (Wang et al., 2003)           | Neurons were protected against cytotoxicity with DHA intake |            |         |
|                        | A (Ozsoy et al., 2011)          | DHA decreased apoptosis of dopaminergic cells in MPTP |            |         |
|                        | A (Samadi et al., 2006)         | DHA reduced 40% of the levodopa-induced dyskinesias in Parkinsonian primates |            |         |
|                        | A (Bousquet et al., 2008)       | DHA preserved DA levels from MPTP-induced neurotoxicity in mice |            |         |
| **DHA + uridine**      | A (Wurtman et al., 2006; Sakamoto et al., 2007) | This combination increased levels of neural phosphatides, proteins in synaptic membranes, and dendritic spines in rodents |            |         |
|                        | A (Cansev et al., 2008)         | DHA and uridine administration also reduced parkinsonian related behaviors and elevated DA levels in 6-OHDA rats |            |         |
| **Melatonin**          | A (Acuna-Castroviejo et al., 1997; Kim et al., 1998; Maharaj et al., 2006a) | Neuronal cell death damage induced by MPTP, 6-OHDA, and iron was protected with Melatonin administration | H (Dowling et al., 2005) | Melatonin improved duration of sleep and reduced sleep disturbances in PD patients |
|                        | A (Mayo et al., 1998, 1999)     | Melatonin blocked apoptosis and necrosis in 6-OHDA and PC12 cells |            |         |
|                        | A (Tapias et al., 2010)         | Striatal DA depletion and DA neuron loss increased after melatonin treatment of rotenone-induced Parkinsonism |            |         |
| **GSH**                | A (Garrido et al., 2011)        | Excessive or reduced GSH levels initiated degeneration of DA neurons |            |         |
|                        | C (Schulz et al., 2000)         | Decreased GSH increased neuron susceptibility to neurotoxins, but did not correlate to DA viability or striatal terminals |            |         |
|                        | A (Kliivenyi et al., 2000)      | Depletion of DA was seen after MPTP treatment in GSH peroxidase-deficient mice |            |         |
|                        | A (Pileblad et al., 1989; Seaton et al., 1996; Wullner et al., 1996) | Low levels of GSH reduced DA neurons after toxin administration |            |         |
| **IP6**                | A/C (Xu et al., 2008, 2011)     | IP6 inhibited MPTP, 6-OHDA, and iron toxicity in cell culture |            |         |
|                        | A (Xu et al., 2008)             | IP6 increased cell survival in MPTP |            |         |
|                        | A (Obata, 2003)                | IP6 suppressed hydroxyl radical formation after MPP+ treatment in rats |            |         |
| **NSAID (ibuprofen + aspirin)** | A/C (Bilodeau et al., 1995; Kaufmann et al., 1997; Aubin et al., 1998; Saini et al., 1998; Casper et al., 2000; Sairam et al., 2003) | NSAID’s protected against neuronal death and dopaminergic neurotoxicity | E (Chen et al., 2003; Ton et al., 2006; Wahner et al., 2007; Gao et al., 2011) | NSAID’s lowered the risk of PD |
|                        | E (Chen et al., 2005; Ton et al., 2006; Driver et al., 2011; Gao et al., 2011) | A reduction in PD risk was observed with Ibuprofen, but not NSAIDS or Acetaminophen | E (Chen et al., 2003; Ton et al., 2006; Wahner et al., 2007; Gao et al., 2011) | |
### Table 1 | Continued

| Neuroprotective agents | Cell culture and animal studies | Human and epidemiological studies |
|------------------------|---------------------------------|----------------------------------|
|                        | Study                           | Results                          | Study                           | Results                                 |
|                        |                                 |                                  |                                 |                                        |
|                        |                                 | NSAIDS showed neuroprotection    | E (Becker et al., 2011)         | NSAIDS’s and aspirin showed no association with altering the risk of PD |
|                        |                                 | in MPTP, 6-OHDA, and in vitro    |                                 | Increased risk of PD shown with moderate aspirin intake |
|                        |                                 |                                  |                                 |                                        |
|                        | A/C (Esposito et al., 2007)     | Ibuprofen protected DA neurons   | E (Bower et al., 2006; Herman et al., 2006) | Ibuprofen reduced the risk of developing PD in humans by 40% |
|                        |                                 | against glutamate toxicity and   |                                 |                                        |
|                        |                                 | decreased MPTP toxicity          |                                 |                                        |
|                        | A (Casper et al., 2000; Morioka et al., 2004, Carrasco et al., 2005) |                                  |                                 |                                        |
|                        |                                 |                                  |                                 |                                        |
| Isradipine             | A (Ilijic et al., 2011)         | Isradipine showed neuroprotection against 6-OHDA | H (Simuni et al., 2010)         | Isradipine was deemed futile for human trials |
|                        |                                 |                                  |                                 |                                        |
| Phenylbutyrate         | C (Gardian et al., 2004; Zhou et al., 2011) | Phenylbutyrate protected DA neurons in the SNpc |                                 |                                        |
|                        | A (Zhou et al., 2011)           | Reduced deterioration in motor and cognitive function in mice |                                 |                                        |
| Ex-4                   | A (Li et al., 2009)             | Protected DA neuron degeneration, preserved DA levels, and improved motor function in rodents |                                 |                                        |
|                        |                                 | Ex-4 protected ventral mesencephalic dopaminergic cells in culture, reverse nigral lesions, and protected against 6-OHDA toxicity |                                 |                                        |
|                        | A/C (Farkavyi et al., 2008; Li et al., 2009) |                                 |                                 |                                        |
| Rasagiline             | C; (Heikkila et al., 1985; Huang et al., 1999; Speiser et al., 1999; Maruyama et al., 2000; Sagi et al., 2001; Youdim et al., 2001a) | Reduces MPTP and 6-OHDA toxicity in PC12 and SH-SYSY cells | H (Hauser et al., 2009; Olanow et al., 2009) | Rasagiline reduced the long-term progression and symptoms in PD |
|                        | A (Kupsch et al., 2001; Sagi et al., 2001). |                                 |                                 |                                        |
|                        | A (Blandini et al., 2004)       | Rasagiline prevented nigrostriatal damage induced by MPTP in primates |                                 | Rasagiline in a Phase III delayed the need for antiparkinsonian drugs and patients had lower scores on the Parkinson’s disease rating scale |
|                        |                                 | Rasagiline increased DA neuron survival in lesioned SNpc and improved motor impairments | H (Rascol et al., 2011)         |                                        |
|                        | C (Murer et al., 2001)          | Rasagiline increased expression of neurotrophins |                                 |                                        |
| Minocycline            | A/C (Du et al., 2001).          | Minocycline blocked MPTP-induced degeneration of DA neurons in the SNpc~ preventing loss of striatal DA and its metabolites. Minocycline treatment also inhibited MPP+ mediated inducible NO synthase expression in vivo and blocked NO-induced neurotoxicity in vitro | H (Investigators, 2006)          | Minocycline was deemed effective in Phase II slowing the progression of PD in patients. An 18-month follow up study showed no safety concerns with its use (Investigators, 2008), leading to Phase III trials |

(Continued)
Table 1 | Continued

| Neuroprotective agents | Cell culture and animal studies | Human and epidemiological studies |
|------------------------|---------------------------------|-----------------------------------|
|                        | Study                           | Results                           | Study                   | Results                     |
|                        |                                 |                                  |                        |                            |
| A (Faust et al., 2009; | DA neuroprotection by           |                                    | H (NET-PD, 2006)       | Reduced progression in PD   |
| Radad et al., 2010)   | Minocycline was seen in a        |                                    |                          | patients in Phase II        |
|                       | Drosophila model of PD and after|                                    |                          |                            |
|                       | rotenone toxicity in rodents     |                                    |                          |                            |
| A (Quintero et al., 2006). | Reduced the number of  |                                    |                          |                            |
|                       | apomorphine-induced rotations in |                                    |                          |                            |
|                       | 6-OHDA-lesioned rats |                                    |                          |                            |
| A/C (Yang et al., 2003) | Minocycline exacerbated MPTP     |                                    |                          |                            |
|                       | damage to DA neurons in vitro   |                                    |                          |                            |
|                       | and in vivo                     |                                    |                          |                            |
| A (Diguet et al., 2004) | Minocycline treatment in primates and mice produced more severe/rapid parkinsonism, behavior deficits, and greater loss of nerve endings | | | |

C, cell culture; A, animal; H, human; and E, epidemiological. Studies showing gender specificity, where males show favorable results are denoted (*).

Minocycline is a semi-synthetic second-generation tetracycline that exerts anti-inflammatory and antioxidant effects (Ryan and Ashley, 1998; Ryan et al., 1998; Faust et al., 2009). Minocycline works by inhibiting the activation of microglia and attenuating the p38 MAPK cascade which reduces inflammatory cytokine synthesis (Figure 1; Yrjanheikki et al., 1998; Tikka et al., 2001; Wu et al., 2002). It is thought that Minocycline’s neuroprotective properties may result from inhibition of NO-mediated neurotoxicity (Du et al., 2001). Additionally, Minocycline may be able to chelate metal ions.

In rodents, Minocycline blocked MPTP-induced degeneration of DA neurons in the SNpc, preventing loss of striatal DA, and its metabolites (Du et al., 2001). Minocycline treatment also inhibited MPP+ mediated NO synthesis expression in vivo and potently blocked NO-induced neurotoxicity in vitro (Du et al., 2001). Potent DA neuroprotection by Minocycline was also observed in a Drosophila model of PD (Faust et al., 2009) and after chronic rotenone toxicity in rodents (Radad et al., 2010). In addition, Minocycline administration reduced the number of apomorphine-induced rotations in 6-OHDA-lesioned rats, reduced TH-positive cell loss and increased the size and fiber density of the remaining nigral cells (Quintero et al., 2006).

Although Minocycline inhibits microglial activation (Wu et al., 2002), other studies have shown it to significantly exacerbate MPTP-induced damage to DA neurons in vitro and in vivo (Yang et al., 2003). Similarly, Minocycline treatment of monkeys and mice produced more severe and rapid parkinsonism, behavior deficits, and greater loss of nerve endings (Diguet et al., 2004). Lack of neuroprotection was shown to be due to the inability of Minocycline to abolish the activation of TNF-α and its receptors, thereby failing to modulate TNF signaling after MPTP administration (Sriram et al., 2006). Minocycline administration in TNF-α knockout MPTP-treated mice increased leakage of the BBB, but these animals did not exhibit a greater loss of neurons (Zhao et al., 2007). In a phase II clinical trial, Minocycline was deemed effective in slowing the progression of PD in patients (Investigators, 2006) and an 18-month follow up study showed no safety concerns, thus paving the way to a phase III trial (Investigators, 2008). Additionally, neuroprotective effects of Minocycline combined with creatine demonstrate additive benefits in reducing PD progression in patients, and is currently in clinical trials (NET-PD, 2006).

CONCLUDING REMARKS

Some neuroprotective agents show promising results for slowing the progression of PD and these are summarized in Table 1. In general, these agents reduce oxidative stress, mitochondrial dysfunction, protein aggregation, inflammation, excitotoxicity, cell death, iron accumulation, or stimulate neurotrophic factors. In an earlier review, caffeine, CoQ10, creatine, Minocycline, and Rasagiline were identified as the top candidates for preventing neurodegenerative diseases (Ravina et al., 2003). However, current...
research suggests that Minocycline, creatine, and Rasagiline are the most promising agents for neuroprotection in PD and all three are now in Phase III trials. In addition, a combination of Minocycline and creatine is in Phase III trials and CoQ10 and creatine is in Phase II. Other promising neuroprotective agents for PD include nicotine, caffeine, Ibuprofen, and DHA since they show strong neuroprotection. More moderate protective effects are observed with melatonin, vitamin D, and UA. In contrast, vitamin E, vitamin C, NSAIDs, aspirin, GSH, and CoQ10 alone show limited or inconsistent results for slowing disease progression. Of the remaining agents, IP6, riboflavin, beta-carotene, Liraglutide, Ex-4, Phenylbutyrate, and Irudipine show promising results in reducing the risk of PD, but further studies are needed to determine if they are neuroprotective in humans. Additionally, caffeine and UA may be promising, but only in male PD patients. These sex-specific effects are a reminder that it is important to assess each PD patient’s response to neuroprotective agents clinically since other unidentifiable variables, such as single nucleotide polymorphisms (SNPs) and hormones, may also affect an individual’s response. Further research addressing the mechanism of the sex differences and how SNPs play a role in the response to neuroprotective agents is needed to optimize a therapeutic approach for treating PD.

ACKNOWLEDGMENTS

The authors thank Jose Santiago and Mich Beales for critical review of the manuscript. This work was supported by the US Army Medical Research and Materiel Command under award number W81XWH-09-0708. Opinions, conclusions, interpretations and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

REFERENCES

Abdin, A. A., and Hamouda, H. E. (2008). Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism. Neuropharmacology 55, 1340–1346.

Acuna-Castroviejo, D., Coto-Montes, A., Gaia Monti, M., Ortiz, G. G., and Reiter, R. J. (1997). Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60, PL23–PL29.

Adhiketty, P. J., and Beal, M. F. (2008). Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 10, 275–290.

Aguiar, L. M., Nobre, H. V. Jr., Macedo, D. S., Oliveira, A. A., Freitas, R. M., Vasconcelos, S. M., Cunha, G. M., Sousa, F. C., and Viana, G. S. (2006). Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 84, 415–419.

Akoa, Y., Maruyama, W., Shimizu, S., Yi, H., Nakagawa, Y., Shamoto-Nagai, M., Youdim, M. B., Tsujimoto, Y., and Naoi, M. (2002a). Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bel-2 and rasagline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82, 913–923.

Akoa, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M. B., and Naoi, M. (2002b). An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagline), enhances expression of anti-apoptotic bel-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105–108.

Akbar, M., Calderon, F., Wen, Z., and Kim, H. Y. (2005). Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl. Acad. Sci. U.S.A. 102, 10858–10863.

Akbar, M., and Kim, H. Y. (2002). Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J. Neurochem. 82, 655–665. Alonso, A., Rodriguez, L. A., Logrosano, M., and Hernandez, M. A. (2007). Gout and risk of Parkinson disease: a prospective study. Neurology 69, 1699–1700.

Ames, B. N., Cathcart, R., Schwiers, E., and Hoestch, P. (1981). Uracil acid provides an antioxidant defense with or without L-dopa in rotenone-induced parkinsonism. Neuropharmacology 20, 1741–1749.

Antolin, I., Mayo, J. C., Sainz, R. M., del Rio Mde.L., Herrera, F., Martin, V., and Rodriguez, C. (2002). Protective effect of melatonin in a chronic experimental model of Parkinson’s disease. Brain Res. 943, 163–173.

Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., and Bennett, D. T. (2004). Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661–666.

Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., and Speizer, F. E. (2003). Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 60, 790–795.

Ascherio, A., LeWitt, P. A., Xu, K., Eberly, S., Watts, A., Matson, W. R., Marras, C., Klebertz, K., Rudolph, A., Bogdanov, M. B., Schwid, S. R., Tennis, T., Tanner, C. M., Beal, M. F., Lang, A. E., Oakes, D., Fahn, S., Shoulson, I., and Schwarzschild, M. A. (2009). Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 1460–1468.

Ascherio, A., Zhang, S. M., Hernandez, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., and Willett, W. C. (2001). Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann. Neurol. 50, 56–63.

Aubin, N., Caret, O., Delfois, A., and Carter, C. (1998). Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71, 1635–1642.

Bar Am, O., Amit, T., and Youdim, M. B. (2004). Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagline and selegiline. Neurosci. Lett. 355, 169–172.

Bar-Am, O., Yoge-Falchak, M., Amit, T., Sagi, Y., and Youdim, M. B. (2004). Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagline and its derivatives, in vivo. J. Neurochem. 89, 1119–1125.

Barbhal, K., Hota, S. K., Baitharu, I., Prasad, D., Singh, S. B., and Ilavazhagan, G. (2009). Irudipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors. Neurobiol. Dis. 34, 230–244.

Bayne, B. J. L., and Potashkin Neuroprotection in Parkinson’s disease. Front. Neurology 3, 230–244.

Barhwal, K., Hota, S. K., Baitharu, I., Prasad, D., Singh, S. B., and Ilavazhagan, G. (2009). Irudipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors. Neurobiol. Dis. 34, 230–244.

Bazan, N. G. (2005). Neuroprotective D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15, 159–166.

Beal, M. F., and Shults, C. W. (2003). Effects of coenzyme Q10 in Huntington’s disease and early Parkinson’s disease. Biofactors 18, 153–161.

Becker, C., Jick, S. S., and Meier, C. R. (2011). NSAID use and risk of Parkinson disease: a population-based case-control study. Eur. J. Neurol. 18, 1336–1342.

Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Daaneus, K., Hindrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., and Wikstrom, L. (2008). Peptidic hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J. Neurosci. Res. 86, 326–358.

Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., and Andersen, J. K. (2002). Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64, 1037–1048.

Bilodeau, J. F., Wang, M., Chung, F. L., and Castonguay, A. (1995). Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice. Free Radic. Biol. Med. 18, 47–54.

Blandini, F., Armentero, M. T., Fanelli, R., Blaugrund, E., and Nappi, G. (2004). Neuroprotective effect of rasagline in a rodent model of Parkinson’s disease. Exp. Neurol. 187, 455–459.
Bousquet, M., Calon, F., and Cicchetti, F. (2011). Impact of omega-3 fatty acids in Parkinson’s disease. Ageing Res. Rev. 10, 453–479.

Bousquet, M., Saint-Pierre, M., Julien, C., Salem, N. Jr., Cicchetti, F., and Calon, F. (2008). Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. FASEB J. 22, 1213–1225.

Bowe, J., Proux, D., Perier, C., and Przedborski, S. (2005a). Toxin-induced models of Parkinson’s disease. NeuroRx 2, 484–494.

Bowe, J., Serrats, J., Mengod, G., Cortes, R., Tolosa, E., and Marin, C. (2005b). Neuroprotection induced by the adenosine A2A antagonist CGS 19755 in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp. Brain Res. 165, 362–374.

Bower, J. H., Maraganore, D. M., Peterson, B. J., Ahlskog, J. E., and Rocca, W. A. (2006). Immunologic disease and the risk of Parkinson disease: a systematic review and meta-analysis. Neurology 67, 494–496.

Burton, G. W., Joyce, A., and Ingold, K. U. (1983). Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch. Biochem. Biophys. 221, 281–290.

Butler, M. W., Burt, A., Edwards, T. L., Zuchner, S., Scott, W. K., Martin, E. R., Vance, J. M., and Wang, L. (2011). Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann. Hum. Genet. 75, 201–210.

Calon, F., Lim, G. P., Morihara, T., Yang, F., Ubeda, O., Salem, N. Jr., Frautschy, S. A., and Cole, G. M. (2005). Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptor-mediated glutamate toxicity in vitro. J. Neurosci. 25, 249–256.

Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., and Ascherio, A. (2005). Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann. Neurol. 58, 963–971.

Chen, H., Mosley, T. H., Alonso, A., and Huang, X. (2009). Plasma urate and Parkinson’s disease in the atherosclerosis risk in communities (ARIC) study. Am. J. Epidemiol. 169, 1064–1069.

Chen, H., Zhang, S. M., Herman, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., and Ascherio, A. (2003). Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059–1064.

Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., Sonnalla, P. K., Castagnoli, K., Castagnoli, N. Jr., and Schwarzschild, M. A. (2001). Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J. Neurosci. 21, RC143.
Horrocks, L. A., and Yeo, Y. K. (1999). Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 40, 211–225.

Huang, W., Chen, Y., Shohami, E., and Weinstock, M. (1999). Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366, 127–135.

Huennekens, F. M. (1956). Flavin nucleotides and flavoproteins. Experientia 12, 1–6.

Ibanez, P., De Michele, G., Bonifati, V., Lohmann, E., Thobois, S., Polak, P., Agid, Y., Heutink, P., Durr, A., and Brice, A. (2003). Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism. Neurology 61, 1429–1431.

Iida, M., Miyazaki, I., Tanaka, K., Kabuto, H., Iwata-Ichikawa, E., and Ogawa, N. (1999). Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838, 51–59.

Ilijic, E., Guzman, J. N., and Surmeier, D. J. (2011). The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol. Dis. 43, 364–371.

Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., Taira, T., Ariga, H., and Shimohama, S. (2007). Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem. 101, 1491–1504.

Investigators, N. N.-P. (2006). A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664–671.

Investigators, N. N.-P. (2007). A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68, 20–28.

Investigators, N. N.-P. (2008). A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31, 141–150.

Jeerakathil, T., Johnson, J. A., Simpson, S. H., and Majumdar, S. R. (2007). Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. Stroke 38, 1739–1743.

Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3), S26–S36; discussion S56–S58.

Jenner, P., Schapira, A. H., and Marsden, C. D. (1992). New insights into the cause of Parkinson’s disease. Neurology 42, 2241–2250.

Jimenez-Jimenez, F. J., Molina, A., Fernandez-Calle, P., Vazquez, A., Cabrera-Valdivia, F., Catalán, M. J., Garcia-Albea, L., Bermejo, E., and Codocin, R. (1993). Serum levels of beta-carotene and other carotenoids in Parkinson’s disease. Neurosci. Lett. 157, 103–106.

Johgatake, M. T., Roghani, M., Negahdar, F., and Hashemi, L. (2004). Protective effect of caffeine against neurodegeneration in a model of Parkinson’s disease in rats: a histochemical evidence. Parkinsonism Relat. Disord. 10, 465–468.

Jones, D. C., Gunasekar, P. G., Borowitz, J. L., and Isom, G. E. (2000). Protective effect of caffeine against mitochondrial iron metabolism and ancillary role in thiol-redox control. J. Neurochem. 74, 2296–2304.

Jump, D. B. (2002). Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13, 155–164.

Kachroo, A., Iritzirry, M. C., and Schwarzschild, M. A. (2010). Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 223, 657–661.

Kaemaf-Rotzoll, D. E., Traber, M. G., Vatter, D., Anderson, J., and Aschner, M. (2003). Caffeine revisited: a vital function in iron metabolism and ancillary role in thiol-redox control. EMBO J. 30, 2044–2056.

Kupsch, A., Gerlach, M., Pupeter, S. C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P., and Oertel, W. H. (1995). Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6, 621–625.

Kupsch, A., Sautter, J., Gotz, M. E., Breithaupt, W., Schwarz, J., Youdim, M. B., Riederer, P., Gerlach, M., and Oertel, W. H. (2001). Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 108, 985–1009.

Kupsch, A., Sautter, J., Schwarz, J., Riederer, P., Gerlach, M., and Oertel, W. H. (1996). 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 16, 1–7.

Kunzner, J. H., Endberg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E. Y., Palfi, S., Roitberg, B. Z., Brown, W. D., Holden, J. E., Pyzalski, R., Taylor, M. D., Carvey, P., Ling, Z., Trono, D., Hantrye, P., Deglon, N., and Aebischer, P. (2000). Neurodegeneration prevented by lentivector delivery of GDNF in primate models of Parkinson’s disease. Science 290, 767–773.

Kumar, C., Igbaria, A., D’Autreieux, B., Blonsan, A. G., Junot, C., Godat, E., Bachawah, A. K., Delaunay-Moisan, A., and Toleedo, M. B. (2011). Glutathione reactivated a vital function in iron metabolism and ancillary role in thiol-redox control. EMBO J. 30, 2044–2056.

Lim, G. P., Calon, E., Morihara, T., Yang, F., Teter, B., Ubeda, O., Salem, N. J., Freathy, S. A., and Cole, G. M. (2005). A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032–3040.

Linville, D. G., Williams, S., Raszkiewicz, J. L., and Arneric, S. P. (1993). Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats. J. Pharmacol. Exp. Ther. 267, 440–448.

Logroscino, G., Marder, K., Graziano, J., Freyjer, G., Slavkovic, V., Lalsome, N., Cote, L., and Mayeux, R. (1997). Altered systemic iron metabolism in Parkinson’s disease. Neurology 49, 714–717.
Maggio, R., Riva, M., Vaglini, F., Foroni, F., Racagni, G., and Corsini, G. U. (1997). Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104, 1113–1123.

Maharaj, D. S., Maharaj, H., Daya, S., and Glass, B. D. (2006a). Melatonin and 6-hydroxydopamine protect against iron-induced neurotoxicity. J. Neurochem. 96, 78–81.

Maharaj, H., Maharaj, D. S., and Daya, S. (2006b). Acetylsalicylic acid and acetaminophen protect against MPP+–induced mitochondrial damage and superoxide anion generation. Life Sci. 78, 2438–2443.

Martin, H. L., and Teismann, P. (2009). Glutathione—a review on its role and significance in Parkinson’s disease. FASEB J. 23, 3263–3272.

Martin, V., Sainz, R. M., Antolin, I., Mayo, J. C., Herrera, F., and Rodriguez, C. (2002). Several antioxidant pathways are involved in astrocyte protection by melatonin. J. Pineal Res. 33, 204–212.

Maruyama, W., Akao, Y., Youdim, M. B., and Naoi, M. (2000). Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoidan, rasagiline and TV1022. J. Neural Transm. Suppl. 58, 59–67.

Mayo, J. C., Sainz, R. M., Uria, H., Antolin, I., Esteban, M. M., and Rodriguez, C. (1998). Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson’s disease. J. Pineal Res. 24, 179–192.

McClean, P. L., Parthasarathy, V., Faivre, E., and Holscher, C. (2010). The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer’s disease. Regul. Pept. 164, 40.

McClean, P. L., Parthasarathy, V., Faivre, E., and Holscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci. 31, 6587–6594.

Merrill, A. H. Jr., Lambeth, J. D., Faunce, D. F., and McCormick, D. B. (1981). Formation and mode of action of flavonoids. Annu. Rev. Nutr. 1, 281–317.

Mesulch, K. G., Kamel, D., Moore, C., Kay, T. S., and Krentz, L. (2002). Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats. Exp. Neurol. 175, 257–274.

Michel, P. P., Hirsch, E. C., and Agid, Y. (2002). Parkinson’s disease: cell death mechanisms. Rev. Neurol. (Paris) 158, 24–32.

Miller, J. W., Selhub, J., and Joseph, J. A. (1996). Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic. Biol. Med. 21, 241–249.

Molina, J. A., de Bustos, F., Jimenez-Escrig, J., Ortega, M., Gasalla, T., Tallon-Barranco, A., Navarro, J. A., Areñas, J., and Enríquez-de Salamanca, R. (1997). Cerebrospinal fluid levels of alpha-tocoferol (vitamin E) in Parkinson’s disease. J. Neural Transm. 104, 1287–1293.

Mores, D. M., Grandinetti, A., Waslien, C. I., Park, C. B., Ross, G. W., and White, L. R. (1996). Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46, 1270–1274.

Morikawa, N., Kumagai, K., Morita, K., Kitayama, S., and Dohi, T. (2004). Nonsteroidal anti-inflammatory drugs potentiate 1-methyl-4-phenylpyridinium (MPP+–)–induced cell death by promoting the intracellular accumulation of MPP+ in PC12 cells. J. Pharmacol. Exp. Ther. 310, 800–807.

Murakami, K., Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., Sakae, N., Fukuyama, H., Hirota, Y., and Nagai, M. (2010). Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson’s disease: a case-control study in Japan. Br. J. Nutr. 104, 757–764.

Murer, M. G., Ian, Q., and Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog. Neurobiol. 63, 71–124.

Nakaso, K., Ito, S., and Nakashima, K. (2008). Caffeine activates the PK3/PI3 Akt pathway and prevents apoptotic cell death in a Parkinson’s disease model of SH-SY5Y cells. Neurosci. Lett. 432, 146–150.

Naveilhan, P., Neveu, L., Wion, D., and Brachet, P. (1996). 1,2-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7, 2171–2173.

NET-PD, N. (2006). A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664–671.

Obata, T. (2003). Phytic acid suppresses 1-methyl-4-phenylpyridinium ion–induced hydroxyl radical generation in rat striatum. Brain Res. 978, 241–244.

Odnas, I. N., Klaudman, L. K., and Adams, J. D. Jr. (1990). MPTP toxicity in the mouse brain and vitamin E. Neurosci. Lett. 108, 346–349.

Oden, D., Ziv, I., Sternin, H., Melamed, E., and Hochman, A. (1996). Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson’s disease. Exp. Neurol. 141, 32–39.

Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., and Tolosa, E. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 361, 1268–1278.

Ozsoy, C., Seval-Celik, Y., Hacıcoholic, G., Yararcoğlu, P., Demir, R., Agar, A., and Aslan, M. (2011). The influence and the mechanism of docosahexanoic acid on a mouse model of Parkinson’s disease. Neurochem. Int. 59, 664–670.

Palacios, N., Weisskopf, M., Simon, K., Gao, X., Schwarzchild, M., and Ascherio, A. (2010). Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson’s disease in men and women. Parkinsonism Relat. Disord. 16, 370–375.

Paraskevas, G. P., Kapaki, E., Petropoulou, O., Anagnostouli, M., Vagenas, V., and Papageorgiou, C. (2003). Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism. J. Neural. Sci. 215, 51–55.

Pearce, R. K., Owen, A., Daniel, S., Jenner, P., and Marsden, C. D. (1997). Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J. Neural Transm. 104, 661–677.

Perlmutter, J. S. (1988). New insights into the pathophysiology of Parkinson’s disease: the challenge of position emission tomography. Arch. Neurol. 45, 293–301.

Perrey, T., Halloway, H. W., Weerasuriya, A., Mouton, P. K., Duffy, K., Mattson, J. A., and Greig, N. H. (2007). Evidence of GLP-1–mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203, 938–966.

Perrey, T. L., Godin, D. V., and Hansen, S. (1982). Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neuropsy. Lett. 33, 305–310.

Perrey, T. L., Yong, V. W., Clavier, R. M., Jones, K., Wright, J. M., Fouilks, J. G., and Wall, R. A. (1985). Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60, 109–114.

Perrey, T. L., Yong, V. W., Hansen, S., Jones, K., Bergeron, C., Fouilks, J. G., and Wright, J. M. (1987). Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 81, 321–331.
Shults, C. W., Haas, R. H., Passov, D., and Beal, M. F. (1997). Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondrial dysfunction from parkinsonian and non-parkinsonian subjects. *Ann. Neurol.* 42, 261–264.

Shults, C. W., Oakes, D., Kieburzt, K., Beal, M. F., Haas, R., Plumb, S., Juncos, J. L., Nutt, J., Shoulson, I., Carter, J., Kompoliti, K., Pernutter, J. S., Reich, S., Stern, M., WATTS, R. L., Kurlan, R., Molho, E., Harrison, M., and Lew, M. (2002). Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch. Neurol.* 59, 1541–1550.

Sian, I., Duster, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P. F., and Fritcher-Turay, C. A. (1994). Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. *Ann. Neurol.* 36, 348–355.

Simon, K. C., Chen, H., Gao, X., Schwarzschild, M. A., and Ascherio, A. (2009). Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. *Mov. Disord.* 24, 1359–1365.

Simuni, T., Burushko, E., Avram, M. J., Miskevics, S., Martel, A., Zadikoff, C., Videnovic, A., Weaver, F. M., Williams, K., and Surmeier, D. J. (2010). Tolerability of isradipine in early Parkinson’s disease: a pilot dose escalation study. *Mov. Disord.* 25, 2863–2866.

Singh, S., Singh, K., Patel, S., Patel, D. K., Singh, C., Nath, C., and Singh, M. P. (2008). Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 (VMAT2) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease phenotype in mouse. *Brain Res.* 1207, 193–206.

Sirivech, S., Driskell, J., and Frieden, E. (1977). NADH-FMN oxidoreductase activity and iron content of organs from riboflavin and iron-deficient rats. *J. Nutr.* 107, 739–745.

Smith, M. P., Fletcher-Jurrjens, C. A., Yurek, D. M., and Cass, W. A. (2006). Calcitril protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. *Neurochem. Res.* 31, 533–539.

Sohmiya, M., Tanaka, M., Tak, N. W., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., and Yamamoto, Y. (2004). Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s disease. *J. Neurosci. Sci.* 223, 161–166.

Speiser, Z., Mayk, A., Eliaish, S., and Cohen, S. (1999). Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. *J. Neural Transm.* 106, 593–606.

Sriram, K., Miller, D. B., and O’Callaghan, J. P. (2006). Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. *J. Neurochem.* 96, 706–718.

Takachi, H., Yanagida, T., Inden, M., Takata, K., Kitamura, Y., Yamakawa, K., Sawada, H., Izuini, Y., Yamamoto, N., Kihara, T., Uemura, K., Inoue, T., Taniguchi, A., Takahashi, R., and Shimohama, S. (2009). Nicotinic receptor stimulation protects nigral dopaminergic neurons in rodent-induced Parkinson’s disease models. *J. Neurosci.* 35, 576–585.

Tan, E. K., Tan, C., Fook-Chong, S. M., Lum, S. Y., Chai, A., Chung, H., Shen, H., Zhao, Y., Teoh, M. L., Yih, Y., Pavanni, R., Chandran, V. R., and Wong, M. C. (2003). Dose-dependent protective effect of coffee, tea, and smoking in Parkinson’s disease: a study in ethnic Chinese. *J. Neurosci. Sci.* 216, 163–167.

Tapia, V., Cannon, J. R., and Greenamyre, J. T. (2010). Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson’s disease model. *J. Neurosci. Res.* 88, 415–427.

Tappel, A. (1962). Vitamin E as the biological lipid antioxidant. *Vitam. Horm.* 20, 493–509.

Tarnopolksy, M. A., and Beal, M. F. (2001). Potential for creatine and other therapies targeting cellular energy dysfunction in neurologic disorders. *Ann. Neurol.* 49, 561–574.

Tatton, N., and Chalmers-Redman, R., and Tatton, N. (2003). Neuroprotection by deprenyl and other propargylamines: gliceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. *J. Neural Transm.* 110, 509–515.

Tikka, T., Fiehich, B. L., Goldstein, G., Keinanen, R., and Koistinaho, J. (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. *J. Neurosci.* 21, 2580–2588.

Tohgi, H., Abe, T., Takahashi, S., and Kikuchi, T. (1993). The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of theBinswanger type, Alzheimer type dementia, and Parkinson’s disease. *J. Neural Transm. Park. Dis. Dement.* Sect. 6, 119–126.

Ton, T. G., Heckbert, S. R., Longstreth, W. T. Jr., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith-Weller, T., and Checkoway, H. (2006). Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. *Mov. Disord.* 21, 964–969.

Toulorge, D., Guerreiro, S., Hild, A., Maskos, U., Hirsch, E. C., and Michel, P. F. (2011). Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.* FASEB J.* 25, 2563–2573.

Traber, M. G., and Sies, H. (1996). Vitamin E in humans: demand and delivery. *Annu. Rev. Nutr.* 16, 321–347.

Trikh, A., Knedels, L., Krause, J., Hanak, T., Lee, D., Gelb, M., and Pallandt, L. (2010). Dacoflamine-induced dopamine neuronal loss in DRBA knockout mice: potential for creatine and creatine phosphate in parkinsonian and nonparkinsonian conditions. *Brain Res.* 36, 348–355.

Weinreb, O., Bar-Am, O., Amit, T., Chilag-Talmon, O., and Youdim, M. B. (2004). Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. *FASEB J.* 18, 1471–1473.

Wu, A., Ying, Z., and Gomez-Pinilla, F. (2004). Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. *J. Neurotrauma* 21, 1457–1467.

Yanagisawa, M., Tanino, Y., Suzuki, H., and Shimohama, S. (2009). Hydroxydopamine-induced neurodegeneration is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. *J. Neurosci.* 22, 1763–1771.

Yih, Y., Pavanni, R., Chandran, V., and Tappin, D. (2003). Potential for creatine and creatine phosphate in parkinsonian and nonparkinsonian conditions. *Brain Res.* 36, 348–355.

Zhou, J., Slusarski, D. C., Schwartz, M. A., and Ascherio, A. (2002). Cognitive decline and risk of Parkinson disease. *J. Neural Transm.* 109, 1427–1439.

Zhou, J., Slusarski, D. C., Schwartz, M. A., and Ascherio, A. (2002). Cognitive decline and risk of Parkinson disease. *J. Neural Transm.* 109, 1427–1439.

Zhou, J., Slusarski, D. C., Schwartz, M. A., and Ascherio, A. (2002). Cognitive decline and risk of Parkinson disease. *J. Neural Transm.* 109, 1427–1439.

Zhou, J., Slusarski, D. C., Schwartz, M. A., and Ascherio, A. (2002). Cognitive decline and risk of Parkinson disease. *J. Neural Transm.* 109, 1427–1439.
Seidl and Potashkin Neuroprotection in Parkinson’s disease

Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., and Albers, D. S. (2003). Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74, 278–285.

Yavin, E., Brand, A., and Green, P. (2002). Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr. Neurosci. 5, 149–157.

Yogeiv-Falach, M., Amit, T., Bar-Am, O., and Youdim, M. B. (2003). The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17, 2325–2327.

Yokota, T., Igarashi, K., Uchihara, T., Jishage, K., Tomita, H., Inaba, A., Li, Y., Arii, M., Suzuki, H., Mizusawa, H., and Arai, H. (2001). Delayed-onset ataxia in mice lacking alphatocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 98, 15185–15190.

Yong, V. W., Perry, T. L., and Krisman, A. A. (1986). Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63, 56–60.

Youdim, M. B., Gross, A., and Fingberg, J. P. (2001a). Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500–506.

Youdim, M. B., Wadia, A., Tatton, W., and Weinstock, M. (2001b). The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939, 450–458.

Yu, Z. F., Bruce-Keller, A. J., Goodman, Y., and Mattson, M. P. (1999). Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res. 53, 613–625.

Zhang, S. M., Hernan, M. A., Chen, H., Spiegelman, D., Willett, W. C., and Ascherio, A. (2002). Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59, 1161–1169.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 12 September 2011; paper pending published: 10 October 2011; accepted: 21 October 2011; published online: 21 November 2011.

Citation: Seidl SE and Potashkin JA (2011) The promise of neuroprotective agents in Parkinson’s disease. Front. Neurosci. 2011 | Volume 2 | Article 68. doi: 10.3389/fneur.2011.00068

This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Neurology.

Copyright © 2011 Seidl and Potashkin. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.